Brokerages expect that Revance Therapeutics Inc (NASDAQ:RVNC) will announce sales of $80,000.00 for the current quarter, according to Zacks. Two analysts have made estimates for Revance Therapeutics’ earnings. The lowest sales estimate is $70,000.00 and the highest is $80,000.00. Revance Therapeutics also reported sales of $80,000.00 in the same quarter last year. The company is scheduled to report its next quarterly earnings report on Monday, February 26th.

According to Zacks, analysts expect that Revance Therapeutics will report full-year sales of $80,000.00 for the current financial year, with estimates ranging from $300,000.00 to $400,000.00. For the next year, analysts forecast that the business will report sales of $430,000.00 per share, with estimates ranging from $200,000.00 to $600,000.00. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Revance Therapeutics.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. During the same quarter last year, the firm earned ($0.64) EPS. The company’s revenue was up .0% on a year-over-year basis.

RVNC has been the subject of several analyst reports. ValuEngine cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 price target on shares of Revance Therapeutics in a report on Tuesday, September 26th. Cowen set a $55.00 price target on shares of Revance Therapeutics and gave the stock a “buy” rating in a report on Wednesday. Piper Jaffray Companies boosted their price target on shares of Revance Therapeutics from $28.00 to $51.00 and gave the stock an “overweight” rating in a report on Tuesday, December 5th. Finally, Mizuho reiterated a “buy” rating and set a $54.00 price target on shares of Revance Therapeutics in a report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. Revance Therapeutics presently has an average rating of “Buy” and a consensus target price of $44.30.

In other news, CFO Lauren P. Silvernail sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $26.83, for a total transaction of $268,300.00. Following the completion of the sale, the chief financial officer now owns 59,006 shares in the company, valued at approximately $1,583,130.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO L Daniel Browne sold 7,600 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total transaction of $189,544.00. Following the sale, the chief executive officer now owns 133,188 shares of the company’s stock, valued at approximately $3,321,708.72. The disclosure for this sale can be found here. 18.86% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the company. Ameriprise Financial Inc. lifted its position in shares of Revance Therapeutics by 1.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,904 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 225 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Revance Therapeutics by 8.1% during the 2nd quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 438 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Revance Therapeutics by 7.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,304 shares of the biopharmaceutical company’s stock worth $483,000 after buying an additional 1,275 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Revance Therapeutics by 6.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 29,112 shares of the biopharmaceutical company’s stock worth $769,000 after buying an additional 1,711 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Revance Therapeutics by 10.4% during the 2nd quarter. Rhumbline Advisers now owns 25,333 shares of the biopharmaceutical company’s stock worth $669,000 after buying an additional 2,395 shares during the last quarter. Institutional investors and hedge funds own 76.69% of the company’s stock.

Revance Therapeutics (NASDAQ RVNC) traded up $0.20 during midday trading on Thursday, reaching $33.95. 284,012 shares of the company’s stock traded hands, compared to its average volume of 337,378. Revance Therapeutics has a 12 month low of $18.00 and a 12 month high of $37.45. The firm has a market cap of $1,214.53, a PE ratio of -8.93 and a beta of 1.62.

COPYRIGHT VIOLATION NOTICE: This story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://theolympiareport.com/2018/01/21/80000-00-in-sales-expected-for-revance-therapeutics-inc-rvnc-this-quarter.html.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Get a free copy of the Zacks research report on Revance Therapeutics (RVNC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.